Latest Pharma Insights
With Profitability In Sight, Legend Turns To New CAR-T Frontiers
The company is advancing a pipeline of allogeneic and in vivo CAR-T therapies for cancer and autoimmune disease. CEO Ying Huang talked to Scrip about what’s next.
Scrip - May 13, 2026
The company is advancing a pipeline of allogeneic and in vivo CAR-T therapies for cancer and autoimmune disease. CEO Ying Huang talked to Scrip about what’s next.
Scrip - May 13, 2026
Takeda Prepares For Rusfertide, Oveporexton, Zasocitinib Launches
The drugmaker said in its full year 2025 earnings call that it plans to draw on existing expertise in neurology, hematology and neurology in the planned launches of the drugs, two of which may win approval in the second half of this year.
Scrip - May 13, 2026
The drugmaker said in its full year 2025 earnings call that it plans to draw on existing expertise in neurology, hematology and neurology in the planned launches of the drugs, two of which may win approval in the second half of this year.
Scrip - May 13, 2026
HistoSonics’ FDA Kidney Filing Would Push Focused Ultrasound Tumor Treatment Beyond The Liver
Minneapolis-based HistoSonics has filed a de novo application with the US FDA on the use of its Edison Histotripsy System to treat kidney tumors. If granted, it would be the Edison’s first cleared indication outside the liver.
Medtech Insight - May 13, 2026
Minneapolis-based HistoSonics has filed a de novo application with the US FDA on the use of its Edison Histotripsy System to treat kidney tumors. If granted, it would be the Edison’s first cleared indication outside the liver.
Medtech Insight - May 13, 2026
Deals Shaping The Medtech And Diagnostics Industries, April 2026
An interactive look at medtech and diagnostics deals made during April 2026. Data courtesy of Biomedtracker.
Medtech Insight - May 13, 2026
An interactive look at medtech and diagnostics deals made during April 2026. Data courtesy of Biomedtracker.
Medtech Insight - May 13, 2026
No Inspection Date, No Warning Letter Clarity: Olympus Carries FDA Uncertainty Into FY2027
Olympus closed FY2026 with $6.4bn in revenue and plans to cut 2,000 jobs – but the harder story is what remains unresolved: no FDA reinspection date for Aizu, no warning letter clarity and products still on ship-hold stretching into the second half of FY2027.
Medtech Insight - May 13, 2026
Olympus closed FY2026 with $6.4bn in revenue and plans to cut 2,000 jobs – but the harder story is what remains unresolved: no FDA reinspection date for Aizu, no warning letter clarity and products still on ship-hold stretching into the second half of FY2027.
Medtech Insight - May 13, 2026
Dr Reddy’s Sets Out Details Of Imminent Semaglutide Launch In Canada
During Dr Reddy’s full-year results call, management set out expectations for the firm’s imminent launch in Canada of the country’s first generic semaglutide rival to Ozempic – while also providing updates on the Indian firm’s biosimilars business.
Generics Bulletin - May 13, 2026
During Dr Reddy’s full-year results call, management set out expectations for the firm’s imminent launch in Canada of the country’s first generic semaglutide rival to Ozempic – while also providing updates on the Indian firm’s biosimilars business.
Generics Bulletin - May 13, 2026
Novo Waves Its Wegovy Pill And High-Dose Jab Flags At ECO
Having slipped behind Eli Lilly in the obesity space, the Danish drugmaker is pushing the clinical benefits of Wegovy pill after its explosive launch in the US.
Scrip - May 13, 2026
Having slipped behind Eli Lilly in the obesity space, the Danish drugmaker is pushing the clinical benefits of Wegovy pill after its explosive launch in the US.
Scrip - May 13, 2026
Roche Aims To Differentiate With AI, High-Burden Diseases
At its 2026 Diagnostics Day, Roche discussed plans for PathAI and differentiation through early testing in oncology, neurology, infectious diseases and cardiometabolic diseases.
Medtech Insight - May 13, 2026
At its 2026 Diagnostics Day, Roche discussed plans for PathAI and differentiation through early testing in oncology, neurology, infectious diseases and cardiometabolic diseases.
Medtech Insight - May 13, 2026
FDA Offers Clarity On New Adverse Event Monitoring System For eMDR Submitters
The US FDA issued an update Tuesday on how its recently consolidated Adverse Event Monitoring System affects stakeholders submitting electronic medical device reports. The new AEMS, which the agency rolled out in March, replaced the decades-old MAUDE.
Medtech Insight - May 13, 2026
The US FDA issued an update Tuesday on how its recently consolidated Adverse Event Monitoring System affects stakeholders submitting electronic medical device reports. The new AEMS, which the agency rolled out in March, replaced the decades-old MAUDE.
Medtech Insight - May 13, 2026
‘Solid Start’ For Bayer Consumer Health Despite US, China Softness
Adjusted sales at Bayer Consumer Health up 5% as the firm's two most important markets remain "challenging."
HBW Insight - May 13, 2026
Adjusted sales at Bayer Consumer Health up 5% as the firm's two most important markets remain "challenging."
HBW Insight - May 13, 2026
Industry Welcomes UK Women’s Health Strategy Update, But Says There’s ‘Still Work To Do’
Bayer, Maxwellia and PAGB have welcomed the UK’s renewed Women’s Health Strategy for prioritizing menopause, menstrual health and prevention, but are pushing for clearer implementation.
HBW Insight - May 13, 2026
Bayer, Maxwellia and PAGB have welcomed the UK’s renewed Women’s Health Strategy for prioritizing menopause, menstrual health and prevention, but are pushing for clearer implementation.
HBW Insight - May 13, 2026
NGOs Threaten Lawsuit Over California SB 54 Plastic Packaging Rules
California SB 54’s ‘weakened’ regulations undermine the law’s recycling and plastic reduction goals, say environmental groups.
HBW Insight - May 13, 2026
California SB 54’s ‘weakened’ regulations undermine the law’s recycling and plastic reduction goals, say environmental groups.
HBW Insight - May 13, 2026
Eli Lilly Positions Oral Foundayo And Lower-Dose Zepbound For Weight Maintenance Market
Fresh late-stage obesity data from Eli Lilly highlights how the next phase of competition in the GLP-1 market may increasingly center on long-term treatment durability and oral therapy adoption.
Scrip - May 13, 2026
Fresh late-stage obesity data from Eli Lilly highlights how the next phase of competition in the GLP-1 market may increasingly center on long-term treatment durability and oral therapy adoption.
Scrip - May 13, 2026
Merck KGaA’s New CEO Targets Early-Stage Assets In M&A Push
Merck KGaA's CEO Kai Beckmann used his first earnings call to raise guidance and map out a four-pillar growth strategy anchored in AI, integrated solutions and targeted M&A.
Scrip - May 13, 2026
Merck KGaA's CEO Kai Beckmann used his first earnings call to raise guidance and map out a four-pillar growth strategy anchored in AI, integrated solutions and targeted M&A.
Scrip - May 13, 2026
Regulatory Recap: UK’s Dormant License Rival Project To Close Applications In June
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - May 13, 2026
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - May 13, 2026
Viatris Targets US GLP-1s With Auto-Injector Strategy
Viatris has ambitions to become “a significant player” in GLP-1s, identifying the US as a key focus as it looks to differentiate itself from other prospective generic competitors through device expertise and the development of “the right auto-injector” to support substitutability.
Generics Bulletin - May 13, 2026
Viatris has ambitions to become “a significant player” in GLP-1s, identifying the US as a key focus as it looks to differentiate itself from other prospective generic competitors through device expertise and the development of “the right auto-injector” to support substitutability.
Generics Bulletin - May 13, 2026
Dr Reddy’s Drops CAR-T, Eyes GLP-1 Upside
Dr Reddy's is recalibrating its portfolio pulling back from the CAR-T segment while advancing near-term opportunities for products like semaglutide in key markets. Impairment charges due to the discontinuation of Immutep’s efti trial have also weighed down the Indian firm’s Q4 earnings.
Scrip - May 13, 2026
Dr Reddy's is recalibrating its portfolio pulling back from the CAR-T segment while advancing near-term opportunities for products like semaglutide in key markets. Impairment charges due to the discontinuation of Immutep’s efti trial have also weighed down the Indian firm’s Q4 earnings.
Scrip - May 13, 2026
Jamjoom Adds Scale As Saudi Localization Momentum Builds
Jamjoom Pharma has announced separate agreements involving Viatris and Pfizer, moving closer toward its Saudi localization strategy and adding impetus behind its broader generics, biosimilars and biologics ambitions.
Generics Bulletin - May 13, 2026
Jamjoom Pharma has announced separate agreements involving Viatris and Pfizer, moving closer toward its Saudi localization strategy and adding impetus behind its broader generics, biosimilars and biologics ambitions.
Generics Bulletin - May 13, 2026
Off-Patent Industry Loses A Champion As Makary Leaves US FDA
Marty Makary’s departure as FDA commissioner means the off-patent industry will lose a figure who has championed its cause in the past year, particularly on biosimilar streamlining and interchangeability.
Generics Bulletin - May 13, 2026
Marty Makary’s departure as FDA commissioner means the off-patent industry will lose a figure who has championed its cause in the past year, particularly on biosimilar streamlining and interchangeability.
Generics Bulletin - May 13, 2026
Celltrion Makes Consumer Health Play With Gifrer Acquisition
Korean biosimilars player Celltrion is diversifying its European business by moving into the consumer health market with the acquisition of France's Gifrer.
HBW Insight - May 13, 2026
Korean biosimilars player Celltrion is diversifying its European business by moving into the consumer health market with the acquisition of France's Gifrer.
HBW Insight - May 13, 2026
Will Novo Launch Wegovy Pill In India As Generics Match Its Semaglutide Sales?
What is the risk-reward balance in India for Novo Nordisk’s Wegovy pills as generics launched in March match the innovator's semaglutide sales in April? Scrip looks for answers in NorstellaLinQ data, India sales data and industry expert comments.
Scrip - May 13, 2026
What is the risk-reward balance in India for Novo Nordisk’s Wegovy pills as generics launched in March match the innovator's semaglutide sales in April? Scrip looks for answers in NorstellaLinQ data, India sales data and industry expert comments.
Scrip - May 13, 2026
Gifrer Acquisition To Boost Celltrion’s French Reach, Portfolio
Celltrion acquiring Gifrer to strengthen its commercial footprint in France, better respond to the French government's biosimilar substitution policy and diversify its product portfolio beyond prescription biologics.
Generics Bulletin - May 13, 2026
Celltrion acquiring Gifrer to strengthen its commercial footprint in France, better respond to the French government's biosimilar substitution policy and diversify its product portfolio beyond prescription biologics.
Generics Bulletin - May 13, 2026
Motif Neurotech Begins Its Biggest Test Yet, And So Does Therapeutic BCI
Motif Neurotech's FDA-authorized trial for a minimally invasive brain implant marks a milestone for therapeutic BCI, but the field still faces fundamental questions about how to read, measure and respond to the brain's role in mental illness.
Medtech Insight - May 13, 2026
Motif Neurotech's FDA-authorized trial for a minimally invasive brain implant marks a milestone for therapeutic BCI, but the field still faces fundamental questions about how to read, measure and respond to the brain's role in mental illness.
Medtech Insight - May 13, 2026
Amgen’s Pavblu Drives?Growth While Prolia/Xgeva Erosion Begins?
Amgen’s quarterly earnings report highlighted both the successes and challenges facing its portfolio.
Generics Bulletin - May 13, 2026
Amgen’s quarterly earnings report highlighted both the successes and challenges facing its portfolio.
Generics Bulletin - May 13, 2026
Deals Shaping The Industry, April 2026
An interactive look at pharma, medtech and diagnostics deals made during April 2026. Data courtesy of Biomedtracker.
In Vivo - May 13, 2026
An interactive look at pharma, medtech and diagnostics deals made during April 2026. Data courtesy of Biomedtracker.
In Vivo - May 13, 2026
Precision’s Proving Ground: The Drug Classes Reshaping Blood Cancer Treatment
In this article, the third of the oncology therapeutic review series, In Vivo looks at hematologic malignancies.
In Vivo - May 13, 2026
In this article, the third of the oncology therapeutic review series, In Vivo looks at hematologic malignancies.
In Vivo - May 13, 2026
Exero Medical Seeks FDA Clearance For xBar Leak-Detection System After Pivotal Trial Success
A pivotal 222-patient study shows Exero Medical's xBar system can detect colorectal anastomotic leaks more than three days earlier than standard care. The company is now seeking FDA clearance, with potential US launch in 2027.
Medtech Insight - May 13, 2026
A pivotal 222-patient study shows Exero Medical's xBar system can detect colorectal anastomotic leaks more than three days earlier than standard care. The company is now seeking FDA clearance, with potential US launch in 2027.
Medtech Insight - May 13, 2026
Makary Out As US FDA Commissioner With Kennedy’s GRAS Change Proposal Still Unfulfilled
HHS Secretary Kennedy and President Trump announce in separate social media posts that Martin Makary, FDA commissioner since March 2025, resigned. FDA Human Foods Program director Kyle Diamantas is acting commissioner.
HBW Insight - May 13, 2026
HHS Secretary Kennedy and President Trump announce in separate social media posts that Martin Makary, FDA commissioner since March 2025, resigned. FDA Human Foods Program director Kyle Diamantas is acting commissioner.
HBW Insight - May 13, 2026
Makary’s Exit Resurrects Questions About US FDA’s Direction Under Trump Administration
Current and former officials warned the FDA is facing a growing loss of institutional knowledge as the Trump-aligned Make America Healthy Again movement pushes for an agency more focused on food.
Scrip - May 13, 2026
Current and former officials warned the FDA is facing a growing loss of institutional knowledge as the Trump-aligned Make America Healthy Again movement pushes for an agency more focused on food.
Scrip - May 13, 2026
With Profitability In Sight, Legend Turns To New CAR-T Frontiers
The company is advancing a pipeline of allogeneic and in vivo CAR-T therapies for cancer and autoimmune disease. CEO Ying Huang talked to Scrip about what’s next.
Scrip - May 13, 2026
The company is advancing a pipeline of allogeneic and in vivo CAR-T therapies for cancer and autoimmune disease. CEO Ying Huang talked to Scrip about what’s next.
Scrip - May 13, 2026
Takeda Prepares For Rusfertide, Oveporexton, Zasocitinib Launches
The drugmaker said in its full year 2025 earnings call that it plans to draw on existing expertise in neurology, hematology and neurology in the planned launches of the drugs, two of which may win approval in the second half of this year.
Scrip - May 13, 2026
The drugmaker said in its full year 2025 earnings call that it plans to draw on existing expertise in neurology, hematology and neurology in the planned launches of the drugs, two of which may win approval in the second half of this year.
Scrip - May 13, 2026
Novo Waves Its Wegovy Pill And High-Dose Jab Flags At ECO
Having slipped behind Eli Lilly in the obesity space, the Danish drugmaker is pushing the clinical benefits of Wegovy pill after its explosive launch in the US.
Scrip - May 13, 2026
Having slipped behind Eli Lilly in the obesity space, the Danish drugmaker is pushing the clinical benefits of Wegovy pill after its explosive launch in the US.
Scrip - May 13, 2026
Eli Lilly Positions Oral Foundayo And Lower-Dose Zepbound For Weight Maintenance Market
Fresh late-stage obesity data from Eli Lilly highlights how the next phase of competition in the GLP-1 market may increasingly center on long-term treatment durability and oral therapy adoption.
Scrip - May 13, 2026
Fresh late-stage obesity data from Eli Lilly highlights how the next phase of competition in the GLP-1 market may increasingly center on long-term treatment durability and oral therapy adoption.
Scrip - May 13, 2026
Merck KGaA’s New CEO Targets Early-Stage Assets In M&A Push
Merck KGaA's CEO Kai Beckmann used his first earnings call to raise guidance and map out a four-pillar growth strategy anchored in AI, integrated solutions and targeted M&A.
Scrip - May 13, 2026
Merck KGaA's CEO Kai Beckmann used his first earnings call to raise guidance and map out a four-pillar growth strategy anchored in AI, integrated solutions and targeted M&A.
Scrip - May 13, 2026
Dr Reddy’s Drops CAR-T, Eyes GLP-1 Upside
Dr Reddy's is recalibrating its portfolio pulling back from the CAR-T segment while advancing near-term opportunities for products like semaglutide in key markets. Impairment charges due to the discontinuation of Immutep’s efti trial have also weighed down the Indian firm’s Q4 earnings.
Scrip - May 13, 2026
Dr Reddy's is recalibrating its portfolio pulling back from the CAR-T segment while advancing near-term opportunities for products like semaglutide in key markets. Impairment charges due to the discontinuation of Immutep’s efti trial have also weighed down the Indian firm’s Q4 earnings.
Scrip - May 13, 2026
Will Novo Launch Wegovy Pill In India As Generics Match Its Semaglutide Sales?
What is the risk-reward balance in India for Novo Nordisk’s Wegovy pills as generics launched in March match the innovator's semaglutide sales in April? Scrip looks for answers in NorstellaLinQ data, India sales data and industry expert comments.
Scrip - May 13, 2026
What is the risk-reward balance in India for Novo Nordisk’s Wegovy pills as generics launched in March match the innovator's semaglutide sales in April? Scrip looks for answers in NorstellaLinQ data, India sales data and industry expert comments.
Scrip - May 13, 2026
Makary’s Exit Resurrects Questions About US FDA’s Direction Under Trump Administration
Current and former officials warned the FDA is facing a growing loss of institutional knowledge as the Trump-aligned Make America Healthy Again movement pushes for an agency more focused on food.
Scrip - May 13, 2026
Current and former officials warned the FDA is facing a growing loss of institutional knowledge as the Trump-aligned Make America Healthy Again movement pushes for an agency more focused on food.
Scrip - May 13, 2026
HistoSonics’ FDA Kidney Filing Would Push Focused Ultrasound Tumor Treatment Beyond The Liver
Minneapolis-based HistoSonics has filed a de novo application with the US FDA on the use of its Edison Histotripsy System to treat kidney tumors. If granted, it would be the Edison’s first cleared indication outside the liver.
Medtech Insight - May 13, 2026
Minneapolis-based HistoSonics has filed a de novo application with the US FDA on the use of its Edison Histotripsy System to treat kidney tumors. If granted, it would be the Edison’s first cleared indication outside the liver.
Medtech Insight - May 13, 2026
Deals Shaping The Medtech And Diagnostics Industries, April 2026
An interactive look at medtech and diagnostics deals made during April 2026. Data courtesy of Biomedtracker.
Medtech Insight - May 13, 2026
An interactive look at medtech and diagnostics deals made during April 2026. Data courtesy of Biomedtracker.
Medtech Insight - May 13, 2026
No Inspection Date, No Warning Letter Clarity: Olympus Carries FDA Uncertainty Into FY2027
Olympus closed FY2026 with $6.4bn in revenue and plans to cut 2,000 jobs – but the harder story is what remains unresolved: no FDA reinspection date for Aizu, no warning letter clarity and products still on ship-hold stretching into the second half of FY2027.
Medtech Insight - May 13, 2026
Olympus closed FY2026 with $6.4bn in revenue and plans to cut 2,000 jobs – but the harder story is what remains unresolved: no FDA reinspection date for Aizu, no warning letter clarity and products still on ship-hold stretching into the second half of FY2027.
Medtech Insight - May 13, 2026
Roche Aims To Differentiate With AI, High-Burden Diseases
At its 2026 Diagnostics Day, Roche discussed plans for PathAI and differentiation through early testing in oncology, neurology, infectious diseases and cardiometabolic diseases.
Medtech Insight - May 13, 2026
At its 2026 Diagnostics Day, Roche discussed plans for PathAI and differentiation through early testing in oncology, neurology, infectious diseases and cardiometabolic diseases.
Medtech Insight - May 13, 2026
FDA Offers Clarity On New Adverse Event Monitoring System For eMDR Submitters
The US FDA issued an update Tuesday on how its recently consolidated Adverse Event Monitoring System affects stakeholders submitting electronic medical device reports. The new AEMS, which the agency rolled out in March, replaced the decades-old MAUDE.
Medtech Insight - May 13, 2026
The US FDA issued an update Tuesday on how its recently consolidated Adverse Event Monitoring System affects stakeholders submitting electronic medical device reports. The new AEMS, which the agency rolled out in March, replaced the decades-old MAUDE.
Medtech Insight - May 13, 2026
Motif Neurotech Begins Its Biggest Test Yet, And So Does Therapeutic BCI
Motif Neurotech's FDA-authorized trial for a minimally invasive brain implant marks a milestone for therapeutic BCI, but the field still faces fundamental questions about how to read, measure and respond to the brain's role in mental illness.
Medtech Insight - May 13, 2026
Motif Neurotech's FDA-authorized trial for a minimally invasive brain implant marks a milestone for therapeutic BCI, but the field still faces fundamental questions about how to read, measure and respond to the brain's role in mental illness.
Medtech Insight - May 13, 2026
Exero Medical Seeks FDA Clearance For xBar Leak-Detection System After Pivotal Trial Success
A pivotal 222-patient study shows Exero Medical's xBar system can detect colorectal anastomotic leaks more than three days earlier than standard care. The company is now seeking FDA clearance, with potential US launch in 2027.
Medtech Insight - May 13, 2026
A pivotal 222-patient study shows Exero Medical's xBar system can detect colorectal anastomotic leaks more than three days earlier than standard care. The company is now seeking FDA clearance, with potential US launch in 2027.
Medtech Insight - May 13, 2026
‘Solid Start’ For Bayer Consumer Health Despite US, China Softness
Adjusted sales at Bayer Consumer Health up 5% as the firm's two most important markets remain "challenging."
HBW Insight - May 13, 2026
Adjusted sales at Bayer Consumer Health up 5% as the firm's two most important markets remain "challenging."
HBW Insight - May 13, 2026
Industry Welcomes UK Women’s Health Strategy Update, But Says There’s ‘Still Work To Do’
Bayer, Maxwellia and PAGB have welcomed the UK’s renewed Women’s Health Strategy for prioritizing menopause, menstrual health and prevention, but are pushing for clearer implementation.
HBW Insight - May 13, 2026
Bayer, Maxwellia and PAGB have welcomed the UK’s renewed Women’s Health Strategy for prioritizing menopause, menstrual health and prevention, but are pushing for clearer implementation.
HBW Insight - May 13, 2026
NGOs Threaten Lawsuit Over California SB 54 Plastic Packaging Rules
California SB 54’s ‘weakened’ regulations undermine the law’s recycling and plastic reduction goals, say environmental groups.
HBW Insight - May 13, 2026
California SB 54’s ‘weakened’ regulations undermine the law’s recycling and plastic reduction goals, say environmental groups.
HBW Insight - May 13, 2026
Celltrion Makes Consumer Health Play With Gifrer Acquisition
Korean biosimilars player Celltrion is diversifying its European business by moving into the consumer health market with the acquisition of France's Gifrer.
HBW Insight - May 13, 2026
Korean biosimilars player Celltrion is diversifying its European business by moving into the consumer health market with the acquisition of France's Gifrer.
HBW Insight - May 13, 2026
Makary Out As US FDA Commissioner With Kennedy’s GRAS Change Proposal Still Unfulfilled
HHS Secretary Kennedy and President Trump announce in separate social media posts that Martin Makary, FDA commissioner since March 2025, resigned. FDA Human Foods Program director Kyle Diamantas is acting commissioner.
HBW Insight - May 13, 2026
HHS Secretary Kennedy and President Trump announce in separate social media posts that Martin Makary, FDA commissioner since March 2025, resigned. FDA Human Foods Program director Kyle Diamantas is acting commissioner.
HBW Insight - May 13, 2026
Dr Reddy’s Sets Out Details Of Imminent Semaglutide Launch In Canada
During Dr Reddy’s full-year results call, management set out expectations for the firm’s imminent launch in Canada of the country’s first generic semaglutide rival to Ozempic – while also providing updates on the Indian firm’s biosimilars business.
Generics Bulletin - May 13, 2026
During Dr Reddy’s full-year results call, management set out expectations for the firm’s imminent launch in Canada of the country’s first generic semaglutide rival to Ozempic – while also providing updates on the Indian firm’s biosimilars business.
Generics Bulletin - May 13, 2026
Regulatory Recap: UK’s Dormant License Rival Project To Close Applications In June
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - May 13, 2026
Generics Bulletin reviews global regulatory developments across the world.
Generics Bulletin - May 13, 2026
Viatris Targets US GLP-1s With Auto-Injector Strategy
Viatris has ambitions to become “a significant player” in GLP-1s, identifying the US as a key focus as it looks to differentiate itself from other prospective generic competitors through device expertise and the development of “the right auto-injector” to support substitutability.
Generics Bulletin - May 13, 2026
Viatris has ambitions to become “a significant player” in GLP-1s, identifying the US as a key focus as it looks to differentiate itself from other prospective generic competitors through device expertise and the development of “the right auto-injector” to support substitutability.
Generics Bulletin - May 13, 2026
Jamjoom Adds Scale As Saudi Localization Momentum Builds
Jamjoom Pharma has announced separate agreements involving Viatris and Pfizer, moving closer toward its Saudi localization strategy and adding impetus behind its broader generics, biosimilars and biologics ambitions.
Generics Bulletin - May 13, 2026
Jamjoom Pharma has announced separate agreements involving Viatris and Pfizer, moving closer toward its Saudi localization strategy and adding impetus behind its broader generics, biosimilars and biologics ambitions.
Generics Bulletin - May 13, 2026
Off-Patent Industry Loses A Champion As Makary Leaves US FDA
Marty Makary’s departure as FDA commissioner means the off-patent industry will lose a figure who has championed its cause in the past year, particularly on biosimilar streamlining and interchangeability.
Generics Bulletin - May 13, 2026
Marty Makary’s departure as FDA commissioner means the off-patent industry will lose a figure who has championed its cause in the past year, particularly on biosimilar streamlining and interchangeability.
Generics Bulletin - May 13, 2026
Gifrer Acquisition To Boost Celltrion’s French Reach, Portfolio
Celltrion acquiring Gifrer to strengthen its commercial footprint in France, better respond to the French government's biosimilar substitution policy and diversify its product portfolio beyond prescription biologics.
Generics Bulletin - May 13, 2026
Celltrion acquiring Gifrer to strengthen its commercial footprint in France, better respond to the French government's biosimilar substitution policy and diversify its product portfolio beyond prescription biologics.
Generics Bulletin - May 13, 2026
Amgen’s Pavblu Drives?Growth While Prolia/Xgeva Erosion Begins?
Amgen’s quarterly earnings report highlighted both the successes and challenges facing its portfolio.
Generics Bulletin - May 13, 2026
Amgen’s quarterly earnings report highlighted both the successes and challenges facing its portfolio.
Generics Bulletin - May 13, 2026
Deals Shaping The Industry, April 2026
An interactive look at pharma, medtech and diagnostics deals made during April 2026. Data courtesy of Biomedtracker.
In Vivo - May 13, 2026
An interactive look at pharma, medtech and diagnostics deals made during April 2026. Data courtesy of Biomedtracker.
In Vivo - May 13, 2026
Precision’s Proving Ground: The Drug Classes Reshaping Blood Cancer Treatment
In this article, the third of the oncology therapeutic review series, In Vivo looks at hematologic malignancies.
In Vivo - May 13, 2026
In this article, the third of the oncology therapeutic review series, In Vivo looks at hematologic malignancies.
In Vivo - May 13, 2026